ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "longitudinal studies"

  • Abstract Number: 251 • 2013 ACR/ARHP Annual Meeting

    Physical Activity Is Associated With Reduced Incident Disability: Evidence From The Osteoarthritis Initiative

    Dorothy D. Dunlop1, Jing Song1, Pamela A. Semanik2, Leena Sharma2, Joan M. Bathon3, Charles Eaton4, Marc C. Hochberg5, Rebecca D. Jackson6, C. Kent Kwoh7, W, Jerry Mysiw6, Michael C. Nevitt8 and Rowland W. Chang1, 1Northwestern University Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, IL, 3Columbia University, New York, NY, 4Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, 5Medicine, University of Maryland School of Medicine, Baltimore, MD, 6Ohio State University, Columbus, OH, 7School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Epidemiology & Biostatistics, UCSF (University of California, San Francisco), San Francisco, CA

     Background/Purpose: Over 56 million people in the U.S. are classified as disabled.  Physical activity is a low cost, broadly applicable approach to improve cardiovascular fitness,…
  • Abstract Number: 2763 • 2013 ACR/ARHP Annual Meeting

    Carotid Atherosclerosis As a Predictor Of Mortality In Rheumatoid Arthritis

    Inmaculada del Rincon1, Roy W. Haas2, Jose Felix Restrepo3, Daniel F. Battafarano4, Daniel H. O'Leary5, Emily Molina1 and Agustin Escalante6, 1Rheumatology, University of Texas Health Science Center, San Antonio, TX, 2Dept. of Medicine-Rheumatology, University of Texas Health Science Center, San Antonio, TX, 3Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, 4Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX, 5Radiology, Tufts University-Boston Campus, Boston, MA, 6Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX

    Background/Purpose: Patients with rheumatoid arthritis (RA) have higher mortality than do persons of the same age and sex without RA. This is due in part…
  • Abstract Number: 2752 • 2013 ACR/ARHP Annual Meeting

    Good, Moderate and Poor Outcome Trajectories Of Pain Severity In Early Symptomatic Knee Osteoarthritis; 5 Year Follow-Up Of Check study

    Janet Wesseling1, Alex N. Bastick2, Sita M.A. Bierma-Zeinstra3 and Johannes W.J. Bijlsma4, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 3Orthopaedics and General Practice, Erasmus MC - University Medical Center, Rotterdam, Netherlands, 4Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Knee pain is often the first sign of knee OA (osteoarthritis) and it is known that its course can be very different between patients over…
  • Abstract Number: 2328 • 2013 ACR/ARHP Annual Meeting

    Tofacitinib, An Oral Janus Kinase Inhibitor, In The Treatment Of Rheumatoid Arthritis: Open-Label, Long-Term Extension Safety and Efficacy Up To 5 Years

    Jürgen Wollenhaupt1, Joel Silverfield2, Eun Bong Lee3, Susan P. Wood4, Ketti K. Terry4, Hiroyuki Nakamura5, Yukako Ohno5, David Gruben4, Birgitta Benda6, Lisy Wang4 and Richard Riese4, 1Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2Healthpoint Medical Group, Tampa, FL, 3Seoul National University, Seoul, South Korea, 4Pfizer Inc, Groton, CT, 5Pfizer Japan Inc, Tokyo, Japan, 6Pfizer Inc, Collegeville, PA

    Background/Purpose: Tofacitinib is a novel, oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). Here we report tofacitinib safety, tolerability, and durability of response…
  • Abstract Number: 1942 • 2013 ACR/ARHP Annual Meeting

    Ultrasound Shows Tenosynovitis to be Frequently Present  as Well As Sensitive to Change in RA Patients On Biologic Medication

    Hilde B. Hammer, Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Ultrasound (US) (grey scale (GS) and power Doppler (PD)) is a sensitive tool for examination of tenosynovitis in patients with rheumatoid arthritis (RA). The…
  • Abstract Number: 1430 • 2013 ACR/ARHP Annual Meeting

    Safety and Efficacy Of Subcutaneous Tocilizumab Monotherapy In a Long-Term Extension Study In Japanese Rheumatoid Arthritis Patients

    Atsushi Ogata, Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Suita, Japan

    Background/Purpose: Tocilizumab (TCZ) blocks interleukin-6-receptor signaling and is an effective rheumatoid arthritis (RA) therapy. The MUSASHI1 and SUMMACTA2 studies showed the efficacy and safety of…
  • Abstract Number: 1303 • 2013 ACR/ARHP Annual Meeting

    Variations In Disease Activity and Therapeutic Management Of Rheumatoid Arthritis In Different International Regions: A Comparison Of Data From The Corrona International and Corrona United States Registries

    Dimitrios A. Pappas1, Kathy Lampl2, Joel M. Kremer3, Sebastião C. Radominski4, Janos Gal5, Fredrik Nyberg6, Anand N. Malaviya7, Aimée Whitworth8, Oscar Luis Rillo9, Allan Gibofsky10, Tatiana Popkova11, Meilien Ho12, Ieda Laurindo13, George W. Reed8, Eduardo Mario Kerzberg14, Laura Horne15, Roman Záhora16, Katherine C. Saunders17, Bernado Pons-Estel18, Alina U. Onofrei19 and Jeffrey D. Greenberg20, 1Columbia University, New York, NY, 2AstraZeneca R&D Wilmington, Wilmington, DE, 3Center for Rheumatology, Albany Medical College, Albany, NY, 4Universidade Federal do Paraná, Curitiba, Brazil, 5Rheumatology, County Hospital, Kecskemet, Hungary, 6AstraZeneca R&D, Mölndal, Sweden, 7Rheumatology, Consultant Rheumatologist, ISIC Superspeciality Hospital, New Delhi-11007-, India, 8CORRONA, Inc., Southborough, MA, 9Hospital Tornú, Capital Federal, Argentina, 10Medicine and Public Health, Hospital for Special Surgery, New York, NY, 11Research Institute of Rheumatology -Russian Academy of Medical Science, Moscow, Russia, 12AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, 13Rheumatology, Universidade de São Paulo, São Paulo, Brazil, 14Rheumatology, J. M. Ramos Mejía Hospital, School of Medicine, University of Buenos Aires, Buenos Aires, Argentina, 15AstraZeneca, Wilmington, DE, 16Revmatologická ambulance, Terezin, Czech Republic, 17Corrona, LLC., Southborough, MA, 18Hospital Provincial de Rosario, Rosario, Argentina, 19University of Massachusetts Medical School, Worcester, MA, 20Rheumatology, NYU Hospital for Joint Diseases, New York, NY

    Background/Purpose: The CORRONA International (C.Intl) rheumatoid arthritis (RA) registry is the first multinational RA registry uniformly collecting baseline and longitudinal data.  We explored variations in…
  • Abstract Number: 1271 • 2013 ACR/ARHP Annual Meeting

    Longitudinal Disease Trajectory Of Juvenile Dermatomyositis

    Lily Siok Hoon Lim1,2, Eleanor Pullenayegum3, Dafna D. Gladman4, Earl D. Silverman5 and Brian M. Feldman6, 1Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, 2Institute of Health Policy Management and Evaluation, University of Toronto, Toronto, ON, Canada, 3Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, ON, Canada, 4Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, 6Rheumatology, Hospital for Sick Children, Toronto, ON, Canada

    Background/Purpose: 1) To determine the longitudinal disease activity trajectory of an inception cohort of Juvenile Dermatomyositis (JDM) patients, 2) To identify predictor(s) for longitudinal disease…
  • Abstract Number: 1232 • 2013 ACR/ARHP Annual Meeting

    Osteoporosis In Rheumatoid Arthritis – Still a Threat In The Biologic Era?

    Glenn Haugeberg1, Torhild Garen2, Hege Sommerseth3, Anne Prøven3 and Knut Helgetveit3, 1Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, 2Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 3Rheumatology, Martina Hansens Hospital, Bærum, Norway

    Background/Purpose: Osteoporosis is a well-known extra articular manifestation in rheumatoid arthritis (RA). In RA biologic disease modifying anti rheumatic drugs (DMARDs) has been shown to…
  • Abstract Number: 1008 • 2013 ACR/ARHP Annual Meeting

    Longitudinal Analysis Of Direct Medical Costs For Systemic Sclerosis Patients: A Population-Based Study

    Natalie McCormick1, Carlo A. Marra2, Eric C. Sayre3 and J. Antonio Avina-Zubieta4, 1Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada, 2Pharm Sciences, Univ of British Columbia, Vancouver, BC, Canada, 3Arthritis Research Centre of Canada, Richmond, BC, Canada, 4Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada

    Background/Purpose: Patients with systemic sclerosis (SSc) have considerable morbidity which may be associated with high health resource utilization.  Studies on health use and costs are…
  • Abstract Number: 901 • 2013 ACR/ARHP Annual Meeting

    Smokers and Overweight Persons Are At Increased Risk Of New Onset Of Severe Foot Pain and Persistent Severe Foot Pain In a Population Study

    Alyssa B. Dufour1, Hylton B. Menz2, Arunima Awale3, Thomas J. Hagedorn3, Virginia A. Casey3, Patricia P. Katz4 and Marian T. Hannan5, 1Institute for Aging Research, Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, 2Lower Extremity and Gait Studies Program, La Trobe University, Bundoora, Victoria 3086, Australia, 3Institute for Aging Research, Hebrew SeniorLife, Boston, MA, 4Medicine, University of California, San Francisco, San Francisco, CA, 5Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

    Background/Purpose:  Few studies have evaluated risk factors for patterns of foot pain in the general population, let alone over time.  An understanding of the possible…
  • Abstract Number: 882 • 2013 ACR/ARHP Annual Meeting

    Association Of a Neutrophil Gene Signature Comprised Of Low Density Granulocyte (LDG)-Enriched Genes With Both Future Systemic Lupus Erythematosus Disease Activity and Poor Longterm Outcomes

    Michelle Petri1, Laurence S. Magder2, Hong Fang1, Jadwiga Bienkowska3, Andrea Dearth4, Norm Allaire5 and Ann Ranger4, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Translational Medicine, Biogen Idec Inc., Cambridge, MA, 4Biogen Idec Inc, Cambridge, MA, 5Biogen Idec Inc., Cambridge, MA

    Background/Purpose: Neutrophils and neutrophil death (NETosis) have a role in the pathogenesis of SLE. A neutrophil gene signature (NGS) exists in SLE, although its association…
  • Abstract Number: 739 • 2013 ACR/ARHP Annual Meeting

    Cardiac Involvement In Granulomatosis With Polyangiitis

    Lucy McGeoch1, Simon Carette2, David Cuthberston3, Gary S. Hoffman4, Nader A. Khalidi5, Curry L Koening6, Carol A. Langford7, Paul A. Monach8, Larry W. Moreland9, Philip Seo10, Ulrich Specks11, Steven R. Ytterberg12, Carol McAlear13, Peter A Merkel14, Christian Pagnoux2 and The Vcrc15, 1Vasculitis clinic, Division of rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 3Biostatistics, University of South Florida, Tampa, FL, 4Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 5Internal Medicine/Rheumatology, McMaster University, Hamilton, ON, Canada, 6Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, 7Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 8Rheumatology, Boston University, Boston, MA, 9Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 10Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 11Mayo Clinic, Rochester, MN, 12Rheumatology Division, Mayo Clinic, Rochester, MN, 13University of Pennsylvania, Philadelphia, PA, 14Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, 15University of Pennsylvania and VA Medical Center, Philadelphia, PA

    Background/Purpose: Prior cohort studies in Europe have found cardiac involvement to be rare in granulomatosis with polyangiitis (GPA) but associated with significant increases in mortality…
  • Abstract Number: 2514 • 2012 ACR/ARHP Annual Meeting

    Racial/Ethnic Trends in Incidence and Prevalence of Rheumatoid Arthritis in a Large Multi-Ethnic Managed Care Population

    Aniket A. Kawatkar1, Cecilia Portugal1, Li-Hao Chu2 and Rajan Iyer3, 1Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, 2Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, 3Department of Research and Evaluation,, Kaiser Permanente Southern California, Pasadena, CA

    Background/Purpose: As epidemiologic studies throughout the world have shown significant variations, we sought to characterize racial differences in longitudinal epidemiologic trends of adult rheumatoid arthritis…
  • Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting

    Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents

    Ioan Ancuta1, Catalin Codreanu2, Ruxandra Ionescu3, Magda Parvu4 and Mihai Bojinca5, 1Internal Medicine, Cantacuzino Hospital, Bucharest, Romania, 2Rheumatology, “Dr. I. Stoia” Center for Rheumatic Diseases, Bucharest, Romania, 3Clinic Hospital "Sf. Maria", Bucharest, Romania, 4Internal Medicine, “N.Gh. Lupu” Clinical Hospital, Bucharest, Romania, 5Internal Medicine, “Dr. I. Cantacuzino” Hospital, Bucharest, Romania

    Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology